Bcal Diagnostics Limited

BCAL Commences US Operations

BCAL Diagnostics Limited (ASX: BDX) (“BCAL” or “the Company”) is pleased to announce that it has established a North Carolina, United States of America, incorporated wholly owned subsidiary, BCAL Diagnostics, Inc. (“BCAL US”) which will commence operations on 2 September 2024.


Highlights:

  • Establishment of BCAL US subsidiary
  • Dr. Klaus-Peter Adam joins BCAL as Director US Research and Product Development
  • Lease of US premises secured and key equipment purchased
  • BCAL US research laboratory to commence operations 2 September 2024

The opportunity to establish BCAL US and commence operations arose out of BCAL research partner Precion Inc undertaking an internal restructure. Key features are:

  • BCAL US being established as a wholly owned subsidiary of BCAL, with BCAL US officeholders being Shane Ryan as President and BCAL directors Jayne Shaw, Dr. John Hurrell and Jonathan Trollip as directors of BCAL US.
  • The purchase from Precion Inc. of equipment is required for the functioning of a US laboratory.
  • The former Chief Technology Officer of Precion, Dr. Klaus-Peter Adam, will join BCAL US, as full-time Director of US Research and Product Development and will oversee BCAL US operations.
  • The BCAL US strategy is quickly building momentum. Dr. Adam is a highly credentialled scientist, specializing in the area of metabolomics and lipidomics who will bring much needed expertise to our growing US team and enhance our global research team. The US program offers BCAL an opportunity to accelerate and validate new products on US patient centric data and gain an in-county understanding of the US diagnostics market. Collaboration with US Physicians is progressing at the first partner two sites, Michigan and Chicago. Dr. John Hurrell (BCAL Board member and Consultant) is based in the US and brings strong industry relevant expertise of the US market, having held senior leadership roles in the US diagnostics space, including Quest Diagnostics. BCAL is also pleased to announce the appointment of MS Cory Dunn who brings a wealth of US and Australian marketing experience and comprehensive knowledge of the US breast cancer network.
BCAL CEO Shane Ryan commented: “This is a wonderful opportunity for BCAL to establish its US presence, which is essential to our global market entry. Shareholders will recall from BCAL’s 2 August 2023 announcement the key role that Dr. Adam played in the 2023 clinical study, and we are extremely fortunate to have gained the services of Dr. Adam on a full-time dedicated basis.”

While the specific financial terms on which BCAL has been able to establish its US operations are commercially confidential, the BCAL board considers the opportunistic establishment of BCAL US as being extremely cost-effective. Additionally, as result of the recent $10.5 million capital raising, BCAL US has been established and can operate over the short-term without needing to raise any further capital.


Click here for the full ASX Release

This article includes content from Bcal Diagnostics Limited, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.

The Conversation (0)

ViiV Healthcare Announces Reimbursement for APRETUDE for HIV-1 Pre-Exposure Prophylaxis under the Non-Insured Health Benefits Program

ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. and Shionogi as shareholders, is pleased to announce that APRETUDE (cabotegravir tablets and extended release injectable suspension) is now covered under the federal Non-Insured Health Benefits (NIHB) Program for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in at risk individuals who are HIV-1 negative. 1

The Non-Insured Health Benefits (NIHB) Program provides eligible First Nations and Inuit people with coverage for a range of health benefits that are not otherwise covered through private, provincial, or territorial health insurance plans or social programs. 2 In Canada approximately 10 per cent of all people living with HIV are Indigenous 3 , despite making up just five per cent of the country's population. 4 Economic, social and systemic barriers, along with the lasting effects of racism and colonialism, all contribute to the disproportionate burden of HIV experienced by Indigenous people. 5

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Dexcom Appoints Jon Coleman as Chief Commercial Officer

DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced the appointment of Jon Coleman as chief commercial officer. In this role, Mr. Coleman will assume responsibility for Dexcom's global commercial organization, including global sales, marketing and customer experience.

Mr. Coleman joins Dexcom with more than 30 years of global commercial leadership experience across multiple healthcare segments and channels. Mr. Coleman served as an executive officer of Masimo Corporation (NASDAQ: MASI), where he held roles of increasing responsibility across his fifteen-year tenure. This included serving as president of Masimo's commercial teams where he oversaw the consolidation of its worldwide hospital sales, OEM, alternate care sales, and clinical teams along with the customer service and hospital conversion teams. Mr. Coleman also held significant roles at Pfizer's (NYSE: PFE) Consumer Healthcare business, leading as vice president and general manager of Canada and the Caribbean region after several years of regional leadership in Asia and Latin America. Across his various roles at these organizations, Mr. Coleman established a track record of scaling operations, developing innovative products, entering new markets, and delivering strong growth performance.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Pfizer Invites Public to View and Listen to Webcast of April 29 Conference Call with Analysts

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday, April 29, 2025. The purpose of the call is to provide an update on Pfizer's results, as reflected in the company's First Quarter 2025 Performance Report, to be issued that morning.

To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors . Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. Participants are advised to register in advance of the conference call.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Cardiol Therapeutics (TSX:CRDL)

Cardiol Therapeutics


Keep reading...Show less

BMO Expands Canadian Depositary Receipt Lineup with 10 New Listings from Europe and Japan

BMO's CDRs offer enhanced portfolio diversification opportunities for Canadian investors enabling them to hold shares in international companies that trade on a Canadian exchange in Canadian dollars

Bank of Montreal (BMO) announced 10 new CDRs will begin trading on the Cboe Canada exchange today. The initial offering of these new CDRs has closed.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Two people wearing lab coats shake hands in business agreement.

What is In-Licensing?

When it comes to investing in pharmaceutical companies, looking at pipelines and research and development prospects is important. But in-licensing is also key when examining these stocks.

In fact, in-licensing deals might be the pharmaceutical industry’s preferred mode of business development these days — perhaps even more so than M&A activity. These agreements can prove to be very fruitful for companies and their share prices.

The in-licensing strategy is likewise attractive to investors, as in-licensing drugs expedites corporate development while also mitigating risk. So let’s clear up some common questions around the strategy. The article below runs through what it means to in-license a drug and how in-licensing differs from an acquisition. It also covers how royalties affect returns. It’s key for investors to be aware of these intricacies so that they can interpret a firm’s actions correctly and elect to buy or sell at the right time.

Keep reading...Show less

Latest Press Releases

Related News

×